Glaxosmithkline Pharmaceutical Share Price
Sector: Biotechnology & Drugs
2805.75 -21.85 (-0.77%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2800.00
Today’s High
2860.00
52 Week Low
1924.30
52 Week High
3147.45
2820.60 -8.00 (-0.28%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2794.20
Today’s High
2856.00
52 Week Low
1921.00
52 Week High
3148.00
Key Metrics
- Market Cap (In Cr) 47540.34
- Beta 0.22
- Div. Yield (%) 1.48
- P/B 24.56
- TTM P/E 52.83
- Peg Ratio 1.5
- Sector P/E 24.5
- D/E 0
- Open Price 2860
- Prev Close 2827.6
Glaxosmithkline Pharmaceutical Analysis
Price Analysis
-
1 Week2.49%
-
3 Months40.17%
-
6 Month15.12%
-
YTD25.61%
-
1 Year40.5%
Risk Meter
- 45% Low risk
- 45% Moderate risk
- 45% Balanced Risk
- 45% High risk
- 45% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 2
- 2
- 1
- Hold
- 1
- 1
- 1
- 2
- Sell
- 1
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 4
- 4
- 4
- 4
Glaxosmithkline Pharmaceutical News
GlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days
1 min read . 18 Feb 2025GlaxoSmithkline shares hit 20% upper circuit as profit jumps fivefold in Q3FY25
2 min read . 17 Feb 2025GSK Q3FY25 Results: Net profit jumps 4X to ₹229 crore; revenue improves 18%
1 min read . 14 Feb 2025Glaxosmithkline Pharmaceutical Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 3749.21
- Selling/ General/ Admin Expenses Total
- 579.7
- Depreciation/ Amortization
- 66.79
- Other Operating Expenses Total
- 601.29
- Total Operating Expense
- 2638.64
- Operating Income
- 1110.57
- Net Income Before Taxes
- 1259.88
- Net Income
- 927.58
- Diluted Normalized EPS
- 54.56
- Period
- 2025
- Total Assets
- 4108.08
- Total Liabilities
- 2156.77
- Total Equity
- 1951.31
- Tangible Book Valueper Share Common Eq
- 114.4
- Period
- 2025
- Cashfrom Operating Activities
- 1289.91
- Cashfrom Investing Activities
- -45.81
- Cashfrom Financing Activities
- -769.42
- Net Changein Cash
- 474.68
- Period
- 2024
- Total Revenue
- 3453.71
- Selling/ General/ Admin Expenses Total
- 1026.91
- Depreciation/ Amortization
- 69.54
- Other Operating Expenses Total
- 61.01
- Total Operating Expense
- 2778
- Operating Income
- 675.71
- Net Income Before Taxes
- 816.19
- Net Income
- 589.96
- Diluted Normalized EPS
- 40.92
- Period
- 2024
- Total Assets
- 3556.62
- Total Liabilities
- 1778.98
- Total Equity
- 1777.64
- Tangible Book Valueper Share Common Eq
- 103.54
- Period
- 2024
- Cashfrom Operating Activities
- 582.02
- Cashfrom Investing Activities
- 8.71
- Cashfrom Financing Activities
- -561.5
- Net Changein Cash
- 29.23
- Period
- 2023
- Total Revenue
- 3251.72
- Selling/ General/ Admin Expenses Total
- 991
- Depreciation/ Amortization
- 65.62
- Other Operating Expenses Total
- 52.24
- Total Operating Expense
- 2513.91
- Operating Income
- 737.81
- Net Income Before Taxes
- 836.4
- Net Income
- 610.69
- Diluted Normalized EPS
- 35.91
- Period
- 2023
- Total Assets
- 3326.58
- Total Liabilities
- 1585.31
- Total Equity
- 1741.27
- Tangible Book Valueper Share Common Eq
- 100.77
- Period
- 2023
- Cashfrom Operating Activities
- 484.23
- Cashfrom Investing Activities
- 807.85
- Cashfrom Financing Activities
- -1543.32
- Net Changein Cash
- -251.25
- Period
- 2022
- Total Revenue
- 3278.03
- Selling/ General/ Admin Expenses Total
- 981.81
- Depreciation/ Amortization
- 68.04
- Other Operating Expenses Total
- 47.06
- Total Operating Expense
- 2599.03
- Operating Income
- 679
- Net Income Before Taxes
- 779.05
- Net Income
- 1694.72
- Diluted Normalized EPS
- 22.13
- Period
- 2022
- Total Assets
- 4633.28
- Total Liabilities
- 1970.32
- Total Equity
- 2662.96
- Tangible Book Valueper Share Common Eq
- 155.16
- Period
- 2022
- Cashfrom Operating Activities
- 810.75
- Cashfrom Investing Activities
- -405.51
- Cashfrom Financing Activities
- -524.24
- Net Changein Cash
- -119
- Period
- 2021
- Total Revenue
- 2925.6
- Selling/ General/ Admin Expenses Total
- 890.82
- Depreciation/ Amortization
- 78.46
- Other Operating Expenses Total
- 68.58
- Total Operating Expense
- 2580.44
- Operating Income
- 345.16
- Net Income Before Taxes
- 453.99
- Net Income
- 358.15
- Diluted Normalized EPS
- 23.41
- Period
- 2021
- Total Assets
- 3114.65
- Total Liabilities
- 1636.39
- Total Equity
- 1478.26
- Tangible Book Valueper Share Common Eq
- 84.7
- Period
- 2021
- Cashfrom Operating Activities
- 577.93
- Cashfrom Investing Activities
- 418.59
- Cashfrom Financing Activities
- -696.14
- Net Changein Cash
- 300.38
- Period
- 2020
- Total Revenue
- 3224.38
- Selling/ General/ Admin Expenses Total
- 1059.87
- Depreciation/ Amortization
- 82.53
- Other Operating Expenses Total
- 60.16
- Total Operating Expense
- 3525.74
- Operating Income
- -301.36
- Net Income Before Taxes
- 305.75
- Net Income
- 93.2
- Diluted Normalized EPS
- 19.51
- Period
- 2020
- Total Assets
- 3133.23
- Total Liabilities
- 1312.63
- Total Equity
- 1820.6
- Tangible Book Valueper Share Common Eq
- 104.54
- Period
- 2020
- Cashfrom Operating Activities
- 490.5
- Cashfrom Investing Activities
- -56.84
- Cashfrom Financing Activities
- -427.62
- Net Changein Cash
- 6.03
- Period
- 2019
- Total Revenue
- 3128.12
- Selling/ General/ Admin Expenses Total
- 975.25
- Depreciation/ Amortization
- 48.45
- Other Operating Expenses Total
- 66.52
- Total Operating Expense
- 2591.14
- Operating Income
- 536.98
- Net Income Before Taxes
- 682.67
- Net Income
- 445.39
- Diluted Normalized EPS
- 25.13
- Period
- 2019
- Total Assets
- 3911.31
- Total Liabilities
- 1771.48
- Total Equity
- 2139.83
- Tangible Book Valueper Share Common Eq
- 122.44
- Period
- 2019
- Cashfrom Operating Activities
- 409.49
- Cashfrom Investing Activities
- -153.45
- Cashfrom Financing Activities
- -358.36
- Net Changein Cash
- -102.33
- Period
- 2025-03-31
- Total Revenue
- 974.37
- Selling/ General/ Admin Expenses Total
- 152.97
- Depreciation/ Amortization
- 14.72
- Other Operating Expenses Total
- 136.27
- Total Operating Expense
- 655.9
- Operating Income
- 318.47
- Net Income Before Taxes
- 358.57
- Net Income
- 262.87
- Diluted Normalized EPS
- 15.52
- Period
- 2025-03-31
- Total Assets
- 4108.08
- Total Liabilities
- 2156.77
- Total Equity
- 1951.31
- Tangible Book Valueper Share Common Eq
- 114.4
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 1289.91
- Cashfrom Investing Activities
- -45.81
- Cashfrom Financing Activities
- -769.42
- Net Changein Cash
- 474.68
- Period
- 2024-12-31
- Total Revenue
- 949.42
- Selling/ General/ Admin Expenses Total
- 124.74
- Depreciation/ Amortization
- 18.8
- Other Operating Expenses Total
- 173.6
- Total Operating Expense
- 676.3
- Operating Income
- 273.12
- Net Income Before Taxes
- 308.1
- Net Income
- 229.88
- Diluted Normalized EPS
- 13.57
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1010.77
- Selling/ General/ Admin Expenses Total
- 150.71
- Depreciation/ Amortization
- 16.86
- Other Operating Expenses Total
- 153.86
- Total Operating Expense
- 701.23
- Operating Income
- 309.54
- Net Income Before Taxes
- 343.81
- Net Income
- 252.5
- Diluted Normalized EPS
- 14.47
- Period
- 2024-09-30
- Total Assets
- 3745.99
- Total Liabilities
- 2073.3
- Total Equity
- 1672.69
- Tangible Book Valueper Share Common Eq
- 97.66
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 730.34
- Cashfrom Investing Activities
- -191.91
- Cashfrom Financing Activities
- -553.34
- Net Changein Cash
- -14.91
- Period
- 2024-06-30
- Total Revenue
- 814.65
- Selling/ General/ Admin Expenses Total
- 151.28
- Depreciation/ Amortization
- 16.41
- Other Operating Expenses Total
- 137.56
- Total Operating Expense
- 600.52
- Operating Income
- 214.13
- Net Income Before Taxes
- 249.4
- Net Income
- 182.33
- Diluted Normalized EPS
- 10.76
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 929.8
- Selling/ General/ Admin Expenses Total
- 172.83
- Depreciation/ Amortization
- 18.1
- Other Operating Expenses Total
- 132.58
- Total Operating Expense
- 690.63
- Operating Income
- 239.17
- Net Income Before Taxes
- 270.62
- Net Income
- 194.48
- Diluted Normalized EPS
- 11.37
- Period
- 2024-03-31
- Total Assets
- 3556.62
- Total Liabilities
- 1778.98
- Total Equity
- 1777.64
- Tangible Book Valueper Share Common Eq
- 103.54
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 582.02
- Cashfrom Investing Activities
- 8.71
- Cashfrom Financing Activities
- -561.5
- Net Changein Cash
- 29.23
- Period
- 2023-12-31
- Total Revenue
- 805.26
- Selling/ General/ Admin Expenses Total
- 141.35
- Depreciation/ Amortization
- 17.11
- Other Operating Expenses Total
- 129.01
- Total Operating Expense
- 767.62
- Operating Income
- 37.64
- Net Income Before Taxes
- 65.43
- Net Income
- 45.72
- Diluted Normalized EPS
- 9.44
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Glaxosmithkline Pharmaceutical Technical
Moving Average
SMA
- 5 Day2818.96
- 10 Day2817.61
- 20 Day2842.3
- 50 Day2786.75
- 100 Day2493.66
- 300 Day2576.31
Glaxosmithkline Pharmaceutical Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Abbott India
- 30650
- 89.15
- 0.29
- 31900
- 25260.2
- 65329.73
- Alkem Laboratories
- 5328.05
- 107.05
- 2.05
- 6440
- 4409.9
- 63820.96
- Glaxosmithkline Pharmaceutical
- 2805.75
- -21.85
- -0.77
- 3147.45
- 1924.3
- 47540.34
- Glenmark Pharmaceuticals
- 1438.5
- -8.8
- -0.61
- 1830.05
- 985.6
- 40687.35
- Biocon
- 341.5
- 2
- 0.59
- 404.6
- 270
- 41000.49
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Abbott India
- 45.91
- 15.34
- 32.31
- 18.83
- Alkem Laboratories
- 34.71
- 6.05
- 18.26
- 13.94
- Glaxosmithkline Pharmaceutical
- 51.85
- 24.56
- 29.26
- 16.77
- Glenmark Pharmaceuticals
- -
- 5.21
- 1.61
- 1.43
- Biocon
- 43.24
- 1.88
- 5.73
- 8.83
Glaxosmithkline Pharmaceutical Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-May-25
- Audited Results & Final Dividend
- 14-Feb-25
- Quarterly Results
- 10-Feb-25
- Quarterly Results
- 29-Oct-24
- Quarterly Results & Interim Dividend
- 02-Aug-24
- Quarterly Results
- 17-May-24
- Audited Results & Final Dividend
- 12-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 17-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 27-Jun-25
- 13-May-25
- AGM
- 30-Apr-25
- 28-Mar-25
- POM
- 28-Jun-24
- 06-Jun-24
- AGM
- 26-Jul-23
- 17-May-23
- AGM
- 26-Jul-22
- 16-May-22
- AGM
- 23-Apr-22
- 22-Mar-22
- POM
- 27-Jul-21
- 18-May-21
- AGM
- 29-May-21
- 27-Apr-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 13-May-25
- 30-May-25
- 30-May-25
- 42
- 24-Oct-24
- 07-Nov-24
- 07-Nov-24
- 12
- 17-May-24
- 31-May-24
- 31-May-24
- 32
- 17-May-23
- 30-Jun-23
- 30-Jun-23
- 32
- 16-May-22
- 08-Jul-22
- 07-Jul-22
- 30
- 17-May-22
- 08-Jul-22
- 07-Jul-22
- 60
- 18-May-21
- 20-Jul-21
- 19-Jul-21
- 30


